Project Grant R43CA306785
- This Project Grant award from the National Cancer Institute (NCI), under the Federal Assistance Listings program CFDA 93.395 Cancer Treatment Research, provides $406,500.00 to support the development of a novel, low-cost, single-use trans-nasal cryotherapy device for esophageal cancer treatment in low-resource settings. The project aims to design and validate a functional prototype of this first-of-its-kind device, which would enable unsedated cryoablation procedures to be administered through...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Bullseye Biodevices, Inc. aims to develop a novel biosensing device for rapidly mapping volumetric tumor margins during surgical interventions for cancer. The key product under development is an electromechanical probe and sensor system that can generate real-time, 3D maps of tumor location and boundaries by measuring biophysical properties like force, deformation, and...
- This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...
- This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,623,261 to Case Western Reserve University to conduct a clinical trial and develop novel molecular technologies for early detection and prevention of esophageal adenocarcinoma. Specifically, the project aims to: 1) demonstrate the efficacy of a non-endoscopic, biomarker-based approach to detect Barrett's esophagus, a precursor to esophageal cancer, in a population...
- This $1,271,498 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division, aims to demonstrate the utility of a transgenic porcine (pig) model of pancreatic cancer for testing novel neoadjuvant therapies and evaluating endoscopic medical devices for imaging and treatment. The key objectives are: 1) to show that the porcine model can...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $399,998 to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The device will incorporate sample collection, nucleic acid biomarker detection via isothermal recombinase polymerase amplification, and a visual readout on lateral flow strips. This work builds on Darwin Biosciences' prior...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $225,229 Project Grant to Navigation Sciences Inc. on September 19, 2025. The grant will fund the development of a novel navigation software system, EndonaviSCI, to address key challenges in lung cancer surgery. The EndonaviSCI system aims to: 1) Ensure accurate localization and placement of a wireless electromagnetic sensor (J-bar) next to the tumor without the need for...
- This federal Project Grant award of $564,414.00 was provided by the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), to assess the feasibility of gastric cancer screening in the United States. The award was granted to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research aimed at developing risk models and identifying high-risk individuals for potential gastric cancer screening. The research...
- This $155,028 Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of an advanced 3D auxetic biodegradable implant for large volume breast reconstruction. The research aims to scale up a novel auxetic architecture design to enhance the structural, mechanical, and biological performance of the implant for improved flexibility, durability, permeability, and tissue regeneration capabilities. Key objectives...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Safeguard Surgical, Inc. (UEI: GCANPGXV3X55) to demonstrate the feasibility of their "LeakGuard" device, a biodegradable barrier intended to prevent anastomotic leaks after esophageal cancer surgery. The $406,500 award, with a project period from September 18, 2025 to August 31, 2026, will be used to 1) assess the mechanical and degradation properties of LeakGuard in esophageal-like conditions, and 2) demonstrate LeakGuard's ability to protect against anastomotic leakage in a porcine model. The goal is to develop an effective, non-surgical method to prevent this serious complication in esophageal cancer patients undergoing esophagectomy procedures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $406.5k | 9/17/25 |